Intratumoral administration of the Toll‐like receptor 7/8 agonist 3M‐052 enhances interferon‐driven tumor immunogenicity and suppresses metastatic spread in preclinical triple‐negative breast cancer. Issue 9 (28th September 2020)

• Record Type: Journal Article
• Authors: Zanker, Damien J; Spurling, Alex J; Brockwell, Natasha K; Owen, Katie L; Zakhour, Jasmine M; Robinson, Tina; Duivenvoorden, Hendrika M; Hertzog, Paul J; Mullins, Stefanie R; Wilkinson, Robert W; Parker, Belinda S
• Is Part Of: Clinical & translational immunology. Volume 9:Issue 9(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-09-28
• Subjects: CD8+ T cell -- immunotherapy -- interferon -- metastasis -- TLR agonist -- triple‐negative breast cancer; Immunologic diseases -- Periodicals; Immunology -- Periodicals; Clinical medicine -- Periodicals; Immune System Diseases -- therapy; Immunotherapy; Immunologic Factors -- therapeutic use; Translational Medical Research; Molecular Targeted Therapy; Clinical medicine; Immunologic diseases; Immunology; Periodicals; Periodicals; Fulltext; Internet Resources; Periodicals; 616.079
• DOI: 10.1002/cti2.1177
• Languages: English
• ISSNs: 2050-0068

Abstract

Abstract: Objectives: Loss of tumor‐inherent type I interferon (IFN) signalling has been closely linked to accelerated metastatic progression via decreased immunogenicity and antitumor immunity. Previous studies in murine models of triple‐negative breast cancer (TNBC) demonstrate that systemic IFN inducers are effective antimetastatic agents, via sustained antitumor CD8 + T‐cell responses. Repeated systemic dosing with recombinant IFNs or IFN inducers is associated with significant toxicities; hence, the use of alternate intratumoral agents is an active area of investigation. It is critical to investigate the impact of intratumoral agents on subsequent metastatic spread to predict clinical impact. Methods: In this study, the local and systemic impact of the intratumoral Toll‐like receptor (TLR) 7/8 agonist 3M‐052 alone or in combination with anti‐PD1 was evaluated in metastatic TNBC models. The IFN‐α receptor (IFNAR1) blocking antibody, MAR1‐5A3, along with immune‐deficient mice and ex vivo assays are utilised to examine the key targets of this agent that are critical for an antimetastatic response. Results: Single intratumoral administration of 3M‐052 reduced mammary tumor growth, induced a T‐cell‐inflamed tumor microenvironment (TME) and reduced metastatic spread to lung. Metastasis suppression was reliant on IFN signalling and an antitumor immune response, in contrast to primary tumor growth inhibition, which was retained in NSG and CD8 + T‐cell‐depleted mice. 3M‐052 action was demonstrated via dendritic cell activation and production of type I IFN and other pro‐inflammatory cytokines to initiate a T‐cell‐inflamed TME and promote tumor cell antigen presentation. Conclusion: This work supports neoadjuvant TLR agonist‐based immunotherapeutics as realistic options for immune activation in the TME and long‐term metastatic protection in TNBC. Abstract : Here, we present preclinical findings on the efficacy of direct tumor adminstration of an interferon inducer in triple‐negative breast cancer. The use of an intratumoral Toll‐like receptor agonist (3M‐052), formulated for retention at the primary tumor site, was sufficient to induce a T‐cell‐inflamed tumor microenvironment in mouse models of triple‐negative breast cancer. A single injection of 3M‐052 into the primary tumor dramatically reduced subsequent metastatic spread to lung, and this was dependent on the antitumor immune response.